Evaluation of the association of response to gemcitabine with markers of HRR deficiency revealed a nonsignificant trend that patients in the Sig3-negative subgroup (reflective of HRR proficient tumors) responded better to gemcitabine compared to patients in the Sig3-positive subgroup (reflective of HRR-deficient tumors), Supplement Fig. 2 .
← all excerpts
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
1
—
—